• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

April 6-7, 2011: Vaccines and Related Biological Products Advisory Committee Meeting Agenda

AGENDA
Food and Drug Administration
Center for Biologics Evaluation and Research
Vaccines and Related Biological Products Advisory Committee
126th Meeting

Hilton Hotel Washington DC North/Gaithersburg
620 Perry Parkway Gaithersburg, MD
April 6 – 7, 2011

Open Session

9:00 a.m.Call to Order and Opening RemarksPatricia Ferrieri, M.D., Acting Chair
9:05 a.m.Conflict of InterestStatement Donald Jehn, M.S., FDA

Topic 1: Presentation of Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, & Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research

9:15 a.m.Overview of Research/Site Visit Process,
Center for Biologics Evaluation and Research (CBER)
Carolyn Wilson, Ph.D., FDA
9:25 a.m.Overview of Office of Vaccines Research and Review (OVRR), CBERKonstantin Chumakov, Ph.D., FDA
9:35 a.m.Overview of Division of Bacterial, Parasitic & Allergenic Products (DBPAP), OVRRJay Slater, M.D., FDA
9:45 a.m.Laboratory of Bacterial PolysaccharidesWillie Vann, Ph.D., FDA
10:00 a.m.Q & A 
10:05 a.m.Open Public Hearing 
10:35 a.m.Break 
10:50 a.m.Closed Session 
11:30 a.m.
 
Lunch 

Topic 2: Demonstration of Effectiveness of Meningococcal Serogroups A, C, Y, and W-135 Conjugate Vaccines in Children Younger Than 2 Years of Age

Open Session

12:30 p.m.Introduction/BackgroundLucia Lee, M.D., FDA
12:40 p.m.Epidemiology of Meningococcal Disease in the U.S.
 
Amanda Cohn, M.D., CDC
 
1:10 p.m.Measurement of Serum Bactericidal Antibody as an Indicator of Vaccine EffectivenessWendell Zollinger, Ph.D.,
Meningococcal Vaccines
Consultant
1:40 p.m.An Approach to Demonstrate Meningococcal
Conjugate Vaccine Effectiveness
in Children Less than 2 Years of Age
Lucia Lee, M.D., FDA
2:10 p.m.Break 
2:30 p.m.Open Public Hearing 
3:00 p.m.Presentation of Discussion PointsLucia Lee, M.D., FDA
 Committee Discussion 
4:00 p.m.Adjourn for the Day 

Day 2 – April 7, 2011

Open Session

8:30 a.m.Call to Order and Opening RemarksPatricia Ferrieri, M.D., Acting Chair
8:35 a.m.Conflict of Interest StatementDonald Jehn, M.S., FDA

Topic 3: Approaches to Demonstrate Effectiveness of Meningococcal Serogroup B Vaccines

8:45 a.m.Introduction/BackgroundMargaret Bash, M.D., MPH, FDA
9:00 a.m.Epidemiology of N. Meningitis Serogroup
B Disease (U.S./Worldwide)
Thomas Clark, M.D., MPH, CDC
9:30 a.m.Molecular Epidemiology and Antigen
Diversity of Candidate Vaccine Targets
Leonard Mayer, Ph.D., CDC
10:15 a.m.Break 
10:30 a.m.An Approach to the Evaluation of Vaccines
To Prevent Group B Meningococcal Disease
Margaret Bash, M.D., MPH, FDA
11:15 a.m.Licensure ApproachRino Rappuoli, Ph.D.,
John Donnelly, Ph.D.
Novartis
11:45 a.m.Lunch 
1:00 p.m.Licensure ApproachKathrin Jansen, Ph.D.
Pfizer, Inc.
1:30 p.m.Open Public Hearing 
2:00 p.m.Break 
2:15 p.m.

Presentation of Discussion Points
Committee Discussion

Margaret Bash, M.D., MPH, FDA
3:30 p.m.
 
Adjourn Meeting